retatrutide phase 2 diabetes trial 🧬 Explained Retatrutide is one of the most promising investigational peptides currently being studied for weight management and metabolic health. Unlike current GLP-1 medications, Retatrutide activates three hormone receptors: • GLP-1 Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

Axe content is medically reviewed or fact checked to ensure factually accurate information

Enhances Insulin Sensitivity: GLP-1 improves insulin sensitivity, particularly in muscle tissue, allowing cells to utilize glucose more efficiently for energy rather than storing it as fat

This conversation should cover: The medical necessity of both treatments The expected duration of prednisolone therapy (short-term versus long-term) Individual risk factors, particularly regarding diabetes or prediabetes Realistic expectations about weight loss outcomes whilst on corticosteroids Monitoring requirements for blood glucose and other metabolic parameters The decision to use both medications should be individualised , weighing the clinical benefits of each treatment against potential complications

Dietary supplements are not required to obtain FDA approval before going to market, and the FDA does not evaluate them for safety or effectiveness before sale

doi: 10.2106/JBJS.CC.23.00506

Additional dose response and kinetic analyses indicated that the differences in insulin release emerged only after several hours of incubation (Fig